Phathom Pharmaceuticals, Inc. PHAT
7.30
0.31
4.43%
as of 25 Sep
- Market cap
- $572.8M
- P/E
- 0.0×
Follow PHAT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
90.07% | 63.97% | 46.58% | 26.42% | |
| (87.53%) | (69.41%) | (52.49%) | (34.32%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(237.06%) | (225.78%) | (103.12%) | (69.23%) | |
Average Days of Receivables |
138.34 | 162.85 | 143.80 | 148.37 | |
Free Cash Flow per Share |
(3.07) | (2.29) | (1.19) | (0.44) | |
Free Cash Flow |
(225.38) | (167.00) | (97.76) | (36.91) | |
Capital Expenditures |
(0.15) | (0.23) | (0.27) | (0.22) | |
Piotroski F-Score |
4.00 | 4.00 | 4.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
280.54% | 168.27% | (1,278.75%) | (1,314.22%) | |
Accounts Receivable Turnover |
3.83 | 3.00 | 3.50 | 3.22 | |
Accounts Payable Turnover |
4.57 | 2.92 | 3.43 | 8.74 | |
Inventory Turnover |
5.58 | 5.18 | 6.38 | 7.35 | |
Average Days of Payables |
20.91 | 80.48 | 75.26 | 47.81 | |
Days of Inventory on Hand |
70.23 | 89.12 | 76.95 | 68.78 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
23.01% | 18.72% | 15.31% | 12.56% | |
Selling, General and Administrative Expense of Revenue |
209.27% | 159.74% | 116.77% | 87.32% | |
Share Based Compensation of Revenue |
20.24% | 16.40% | 14.01% | 11.33% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.82 | 0.75 | 0.62 | 0.37 | |
Depreciation/Fixed assets |
3.06 | 3.43 | 3.67 | 3.96 | |
Capex/Depreciation |
(0.04) | (0.06) | (0.07) | (0.06) | |
Revenue per Share |
2.01 | 2.40 | 2.50 | 2.86 | |
Operating CF per Share |
(3.07) | (2.29) | (1.19) | (0.44) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(186.53%) | (126.35%) | (76.77%) | (41.34%) |
Columns are period end dates